Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide

Thompson, 2013, Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline, J Urol, 190, 441, 10.1016/j.juro.2013.05.032 The Medical Research Council Prostate Cancer Working Party Investigators Group, 1997, Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial, Br J Urol, 79, 235, 10.1046/j.1464-410X.1997.d01-6840.x Heath, 2010, A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3′-diindolylmethane) in castrate-resistant, non-metastatic prostate cancer, Am J Transl Res, 2, 402 Smith, 2005, Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer, J Clin Oncol, 23, 2918, 10.1200/JCO.2005.01.529 Wallis, 2018, Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis, Eur Urol, 73, 834, 10.1016/j.eururo.2017.10.002 Hussain, 2018, PROSPER: a phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC), J Clin Oncol, 36, 3, 10.1200/JCO.2018.36.6_suppl.3 Smith, 2018, Apalutamide treatment and metastasis-free survival in prostate cancer, N Engl J Med, 378, 1048, 10.1056/NEJMoa1715546 Bucher, 1997, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials, J Clin Epidemiol, 50, 683, 10.1016/S0895-4356(97)00049-8 Wells, 2009 Song, 2003, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses, BMJ, 326, 472, 10.1136/bmj.326.7387.472